Cancer-Focused Arrivent Biopharma Eyes $150M IPO
By Yeji Jesse Lee · January 22, 2024, 6:48 PM EST
Lung cancer-focused Arrivent Biopharma Inc. set a price range for its planned initial public offering Monday, saying it plans to offer 8.3 million shares at a price range of $17 to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login